Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 5.60%
As of Friday, July 31, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 5.60%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Commentary & Analysis
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 9.16%
As of Tuesday, July 28, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 9.16%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 6.47%
As of Monday, July 27, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 6.47%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 6.04%
As of Thursday, July 09, Verrica Pharmaceuticals Inc.’s VRCA share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 7.08%
As of Wednesday, July 08, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 7.08%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $90.4 | $569.9 | 21% |
|
| Shares Out (Mil) | 21.3 | 44.8 | 32% |
|
| Institutional Ownership | 43.7% | 84.6% | 19% |
|
| Float (Mil) | 7.9 | 45.1 | 17% |
|
| Beta | 1.49 | 0.67 | 82% |
|
| Avg Daily Volume (000s) | 33 | 294 | 24% |
|
| Price Change (52-week) |
(15.7%) | 65.2% | 34% |
|
| Growth | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | 16.0% | (2.0%) | 65% |
|
| EPS (5yr) | 37.1% | 14.9% | 86 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (35.8%) | (14.9%) | 14% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.467) | ($1.733) | ($1.243) | |
| Month Ago EPS | ($0.453) | ($1.733) | ($1.243) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | ($0.520) | ($2.075) | ($1.705) | |
| Year/Year Chg | 2.9% | 3.2% | (69.0%) | |
| Financials | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $37 | $230 | 18% |
|
| Net Income (TTM) (Mil) | ($18) | ($11) | 25% |
|
| EPS (TTM) | ($1.310) | ($0.600) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($14) | ($6) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $7 | 16% |
|
| Enterprise Value (Q1) (Mil) | $78 | $493 | 19% |
|
| Valuation | VRCA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.66 | 2.89 | 81% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 61.5% | 65.9% | 74% |
|
| Net Margin | (48.0%) | (0.2%) | 12% |
|
| ROA | (44.0%) | (25.5%) | 13% |
|
| ROE | na | (21.4%) | na |
|
| Liabilities to Assets | 58.6% | 35.5% | 52% |
|
| F-Score | 6 | 3 | 69% |
|
Verrica Pharmaceuticals Inc. did not pass any screens on 7/30/2026.
